Allorion Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 33

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 13

Allorion Therapeutics General Information

Description

Developer of small-molecule drugs designed to treat cancer and autoimmune diseases. The company develops mutant selective and isoform-specific drugs in non-conventional ways for well-known targets, enabling doctors to improve drug efficacy and prevent patient resistance.

Contact Information

Website
www.alloriontx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 22 Strathmore Road
  • Natick, MA 01760
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 22 Strathmore Road
  • Natick, MA 01760
  • United States
+1 (781)

Allorion Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allorion Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B) 30-Jan-2023 Completed Clinical Trials - Phase 2
3. Accelerator/Incubator 08-Nov-2022 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 23-Nov-2021 $40M $40M Completed Pre-Clinical Trials
1. Seed Round 23-Nov-2020 Completed Pre-Clinical Trials
To view Allorion Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Allorion Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small-molecule drugs designed to treat cancer and autoimmune diseases. The company develops mutant selectiv
Drug Discovery
Natick, MA
33 As of 2025

Shelton, CT
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Allorion Therapeutics Competitors (34)

One of Allorion Therapeutics’s 34 competitors is Intensity Therapeutics, a Formerly PE-Backed company based in Shelton, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intensity Therapeutics Formerly PE-Backed Shelton, CT
Genprex Formerly VC-backed Austin, TX
Scorpion Therapeutics Venture Capital-Backed Boston, MA
MatriSys Bioscience Venture Capital-Backed La Jolla, CA
Nuvalent Formerly VC-backed Cambridge, MA
You’re viewing 5 of 34 competitors. Get the full list »

Allorion Therapeutics Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 15

    Pending

  • Expiring in next 12 mo

Allorion Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250026763-A1 Egfr inhibitors and methods of use thereof Pending 25-May-2023
AU-2023359057-A1 Phosphoramidate compounds and uses thereof Pending 09-Oct-2022
AU-2023314327-A1 Aminoheteroaryl kinase inhibitors Pending 29-Jul-2022
EP-4562000-A1 Aminoheteroaryl kinase inhibitors Pending 29-Jul-2022
EP-4532473-A1 Aminoheteroaryl kinase inhibitors Pending 27-May-2022 C07D405/12
To view Allorion Therapeutics’s complete patent history, request access »

Allorion Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allorion Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
3Sbio Corporation Minority
INCE Capital Venture Capital Minority
LongRiver Investments Venture Capital Minority
Roche Accelerator Accelerator/Incubator
Elikon Venture Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

Allorion Therapeutics FAQs

  • When was Allorion Therapeutics founded?

    Allorion Therapeutics was founded in 2020.

  • Where is Allorion Therapeutics headquartered?

    Allorion Therapeutics is headquartered in Natick, MA.

  • What is the size of Allorion Therapeutics?

    Allorion Therapeutics has 33 total employees.

  • What industry is Allorion Therapeutics in?

    Allorion Therapeutics’s primary industry is Drug Discovery.

  • Is Allorion Therapeutics a private or public company?

    Allorion Therapeutics is a Private company.

  • What is Allorion Therapeutics’s current revenue?

    The current revenue for Allorion Therapeutics is .

  • How much funding has Allorion Therapeutics raised over time?

    Allorion Therapeutics has raised $90M.

  • Who are Allorion Therapeutics’s investors?

    3Sbio, INCE Capital, LongRiver Investments, Roche Accelerator, and Elikon Venture are 5 of 13 investors who have invested in Allorion Therapeutics.

  • Who are Allorion Therapeutics’s competitors?

    Intensity Therapeutics, Genprex, Scorpion Therapeutics, MatriSys Bioscience, and Nuvalent are some of the 34 competitors of Allorion Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »